v3.26.1
Consolidated Statements of Net Income/(Loss) and Comprehensive Income/(Loss) - USD ($)
 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2024
Expenses      
Sales and marketing $ 218,485 $ 483,530 $ 80,603
Research and development 1,466,653 342,168 954,593
General and administrative 892,264 1,209,847 557,904
Professional and consulting fees 3,654,843 1,623,209 1,158,484
Loss before other items (6,232,245) (3,658,754) (2,751,584)
Other items      
Other income 292,247 879,344
Other expense (1,500,000)
Depreciation (5,266) (4,268) (240)
Interest income 263,370 95,787 2,134
Interest expense (9,522) (9,270) (52,941)
Foreign exchange loss (1,144) (7,317) (2,695)
Listing expense (41,481,605)
Transaction expense (2,461,025)
Gain on debt settlement 281,500
Fair value gain/(loss) on convertible note 3,357,628 (5,157,397)
Fair value gain/(loss) on warrant liability (15,380) 694,516 (306,250)
Fair value gain/(loss) on promissory notes 705,565 (108,288)
Fair value loss on warrant exchange (185,064)
Fair value gain on investment in Psyence Labs Ltd 427,000 22,967
Fair value loss on digital assets (110,242)
Share of losses from Associate (45,239)
NET INCOME/(LOSS) (6,936,421) 1,011,790 (51,159,048)
Other comprehensive income/(loss)      
Foreign exchange gain/(loss) on translation 44,979 (9,859) 3,715
Other comprehensive income 191,982
TOTAL COMPREHENSIVE INCOME/(LOSS) $ (6,891,442) $ 1,001,931 $ (50,963,351)
Income/(Loss) per share - basic (in Dollars per share) $ (12.56) $ 32.76 $ (29,214.06)
Income/(Loss) per share - diluted (in Dollars per share) $ (12.56) $ 32.76 $ (29,214.06)
Weighted average number of outstanding shares - basic (in Shares) 552,282 30,887 1,744
Weighted average number of outstanding shares - diluted (in Shares) 552,282 30,887 1,744